

AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the specification:

Listing of the Claims:

1. (Previously Presented) A carrier with a non-cationic surface, which can accumulate on a damaged endothelial cell site of a tissue comprising endothelial cells, wherein the carrier comprises a phospholipid having a phosphatidylcholine group, a sterol, and 1,5-dipalmitoyl-L-glutamate-N-succinic acid ("DPEA").
2. (Original) A carrier according to claim 1, wherein the surface is a membrane.
3. (Original) A carrier according to either one of claims 1 and 2, wherein the tissue is a vessel.
4. (Original) A carrier according to claim 3, which can diffuse outside the vessel.
5. (Previously Presented) A carrier according to claim 3, wherein the vessel is a blood vessel.
6. (Original) A carrier according to claim 1, wherein the damage reaches an endothelial cell.

7. (Original) A carrier according to claim 1, wherein the damage comprises those that result from laser, inflammation, ischemic disorder, ischemia-reperfusion damage, bacterial toxin, oxidative stress, tumor or thrombus formation, or bleeding.

8. (Original) A carrier according to claim 7, wherein the inflammation is brain edema.

9. (Original) A carrier according to claim 7, wherein the ischemic disorder is cerebral ischemic disorder.

10. (Original) A carrier according to claim 7, wherein the ischemia-reperfusion damage is ischemia-reperfusion-induced organ damage.

11. (Cancelled)

12. (Previously Presented) A pharmaceutical composition comprising the carrier according to claim 1 incorporating or carrying a drug.

13. (Original) A pharmaceutical composition according to claim 12, which functions as a drug for controlling a platelet function.

14. (Original) A pharmaceutical composition according to claim 13, wherein the platelet function to be controlled comprises hemostasis, antithrombotic formation, thrombolysis or antiatherogenic action.

15. (Original) A pharmaceutical composition according to claim 12, wherein the drug is at least one selected from a group consisting of substances that are activated by light, change in temperature, change in pH, ultrasound, uptake of an inflammation-

Amendment In Response to February 19, 2010 Final Office Action and
Petition for a One-Month Extension of Time (RCE Submission)

mediating cell or enzyme degradation; hemostatic agents; antithrombotic agents; thrombolytic agents; antitumor agents; and antiatherogenic agents.

16. (Original) A pharmaceutical composition according to claim 15, wherein the inflammation-mediating cell is a lymphocyte, a leukocyte, a macrophage or a platelet.

17. (Previously Presented) A drug delivery method comprising *in vivo* administering the pharmaceutical composition of claim 12 and allowing said composition to accumulate on a damaged endothelial cell site of a tissue.

18. (Currently Amended) A drug control method comprising *in vivo* administering the pharmaceutical composition of claim 12; allowing ~~the pharmaceutical~~ said composition according to claim 12 to accumulate on a damaged endothelial cell site of a tissue; and allowing the drug to act on the damaged endothelial cell site.

19. (Original) A method according to claim 18, wherein the action of the drug is controlled by accumulation of the carrier, diffusion of the carrier or activation of the carrier.

20. (Original) A method according to any one of claims 17 to 19, wherein the tissue is a vessel.

21. (Original) A method according to claim 20, wherein the vessel is a blood vessel.

22.-27. (Cancelled)

Amendment In Response to February 19, 2010 Final Office Action and
Petition for a One-Month Extension of Time (RCE Submission)

28. (New) A carrier with a non-cationic surface, which can accumulate on a damaged endothelial cell site of a tissue comprising endothelial cells, wherein the carrier comprises a phospholipid having dipalmitoylphosphatidylcholine ("DPPC"), cholesterol, 1,5-dipalmitoyl-L-glutamate-N-succinic acid ("DPEA") and a polyethyleneglycol lipid.

29. (New) A carrier according to claim 28, wherein the molar ratio of DPPC/cholesterol/DPEA is 5/5/10.